SAMPLE REPORT · fictional profile for illustration · your report is personalized to your own intake
90-Day Comprehensive Report · this client · PR-90D-SAMPLE-2026Enable "Background graphics" in your browser print dialog for full color printing
PeptideReport.ai — 90-Day ComprehensivePR-90D-SAMPLE-2026 · July 8, 2026
Your 90-Day Comprehensive Report
Personalized educational framework, phased across 90 days at the Advanced experience level · Not medical advice or a clinical recommendation
Age / Sex
48 · Female
Height
5′ 5″
Weight
158 lb
Goal weight
145 lb
Experience
Advanced
Sleep / night
Poor ⚠
Educational use only — paid report tier. This report is AI-assisted and is not medical advice, diagnosis, treatment, or prescribing.
Research compounds require professional guidance, sterile sourcing, and individual evaluation.
Same-day use does not mean same-syringe compatibility — never assume without professional confirmation.
All dosing, timing, reconstitution, and protocol references are educational frameworks only.
Dose figures referenced for research compounds are educational reference from published trials (Jastreboff, NEJM 2023), used only under clinician supervision.
This 90-Day Comprehensive Report provides a practical educational framework — including compound context, protocol dose references, reconstitution concepts, timing organization, safety cautions, and a structured starting guide. This report is educational scaffolding, not a prescription. It is designed to help you have a more informed, specific, and productive conversation with your licensed professional.
Your focus"Perimenopause has upended my sleep, energy, and body. Hot flashes at night, drive is gone, and the weight won’t move."
Profile summary
Goal delta
−13 lb
Experience level
Advanced
GLP-1 in plan
Tirzepatide
Prior peptide use
None
Areas of concern selected
Hormone SignalingSkin / AestheticEnergy / MitochondrialLibido / Sexual WellnessLongevity / Cellular HealthWeight Loss / Body Composition
Symptom severity
Low energyHigh
Afternoon crashHigh
Poor sleepHigh
Waking tiredHigh
Low libidoHigh
Low vitalityHigh
Perimenopause / menopauseHigh
Hot flashes / night sweatsHigh
Lifestyle snapshot
Sleep
Poor ⚠
Activity
Light
Exercise
None
Protein
Moderate
Hydration
Not specified
Alcohol
Glass of wine most nights
Sleep flag: Poor sleep quality falls below the threshold associated with healthy glucose regulation, GH release, and hormonal recovery — directly relevant to the metabolic, energy, and hormone concerns in this profile.
🚩Read this before you continue
What you're about to see may surprise you.
The section below shows the wellness categories matched to your profile — along with real compound names studied in each category. A list of compound names without the framework behind them is where confusion typically begins. This report goes further — providing the practical educational framework behind every compound listed.
Knowing the names is only the beginning. Understanding how to use them is an entirely different conversation.
The compounds listed above are educational examples only — not a recommendation, not a protocol, and not a complete picture. This is an important limitation of any category-level overview. Knowing which peptide categories may align with your goals is useful, but it does not explain how those categories should be interpreted in practice.
Peptide education becomes significantly more complex once the following enter the conversation:
Vial strengthReconstitution conceptsDose interpretationSyringe-unit mathTiming considerationsToleranceSafety distinctionsCompatibility questionsSame-vial vs. same-syringeFasting contextFoundational vs. later-stage compoundsLong-horizon pathways
Many people reach this point with a list of possible compounds but no clear structure for understanding them. That gap leads to confusion, unnecessary spending, mismatched expectations, or reliance on incomplete information from forums, videos, and informal protocols.
The sections that follow provide the practical educational framework needed to understand how these compounds are commonly organized, interpreted, and approached — so you can make the most informed decisions possible for your situation.
Section 2 — How these categories interconnect
Understanding the relationship between your matched areas
Your matched areas are not separate problems to solve one at a time — they are several expressions of the same picture. Hormone Signaling is the through-line you flagged as your primary focus, and the plan is anchored there; Skin / Aesthetic, Energy / Mitochondrial, Libido / Sexual Wellness, Longevity / Cellular Health, and Weight Loss / Body Composition tend to move alongside it. Stabilizing the anchor areas first creates a cascade across the supporting ones — which is why the plan is sequenced foundation-first.
⚠️Before you go further — critical handling and sourcing awareness
The compounds referenced in this report are only as reliable as the way they are handled, sourced, and prepared. This is one of the most overlooked areas in peptide education — and one of the most consequential. Understanding compound categories is step one. Understanding what can compromise them before they ever reach you is equally important.
🧪
Never mix peptides into the same vial
Combining multiple peptides into one vial — before or after reconstitution — can create an unstable, unpredictable solution. Different peptides may have conflicting pH requirements, solubility profiles, and degradation patterns. Once combined, you may no longer have a reliable product. The mixture may oxidize, precipitate, lose potency, or become impossible to evaluate. A poorly mixed vial can destroy an entire plan before the first use.
🏷️
Branded blend names are not proof of quality or compatibility
Many peptide products are marketed under consumer-friendly stack names that make complex mixtures sound simple and targeted. These names do not prove stability, compatibility, sterility, or appropriateness for the individual user.
Wolverine StackGlow BlendKLOW BlendRecovery BlendGH BlendFat Loss StackLongevity BlendSuper StackAll-in-One Formula
⚗️
GHK-Cu requires special separation — always
GHK-Cu contains copper, which may accelerate degradation or create compatibility problems when combined with other peptides in the same vial. GHK-Cu must always be handled separately and never mixed with other compounds unless a qualified pharmacy has specifically verified the formulation. This includes products marketed under "Glow" or "KLOW" style blend names.
💧
bacteriostatic (BAC) water quality can ruin an entire vial
Reconstitution solution is not a minor supply item. A contaminated, improperly formulated, or chemically incompatible diluent can compromise a peptide immediately — even if the peptide itself was correctly sourced and stored. Results become impossible to evaluate fairly.
❌ Avoid these sourcing approaches for BAC water and reconstitution supplies
✗Amazon "BAC water" listings or reconstitution kits
✗Anonymous online sellers and marketplace storefronts without verified pharmacy credentials
✗Social media vendors and generic "research supply" websites
✗Unlabeled, relabeled, or unverified reconstitution products
✓ Preferred standard
Use only sterile, pharmaceutical-grade bacteriostatic water or an appropriate qualified diluent obtained through a licensed pharmacy, qualified medical source, or licensed professional. A peptide plan is only as reliable as the compounds, the reconstitution process, the storage conditions, and the compatibility decisions behind it.
🚨Critical Warning: Avoid Peptide Scams and Ineffective Delivery Systems
Beware of companies promoting sublingual drops, lozenges, oral capsules, nasal sprays, or any "easy" non-injection delivery methods. These products are almost always ineffective and prey on people looking for convenience.
Most research peptides are large, water-soluble molecules rapidly broken down by enzymes in the mouth, stomach, or nasal mucosa. Scientific literature consistently shows they have extremely poor or zero meaningful absorption through these routes. Only subcutaneous injection has demonstrated reliable absorption and consistent results in laboratory research settings.
If a company is pushing sublingual, oral, or other "no-needle" options as effective alternatives, it is almost certainly a scam. Always verify any peptide product comes from a reputable supplier with third-party testing (COA — Certificate of Analysis).
A limited number of compound-specific, route-specific exceptions are supported by research:
✓ Intranasal: Semax and Selank (developed in Russia specifically as nasal sprays, documented nose-to-brain delivery) · Oxytocin (~11% nasal bioavailability, extensively studied) · Epithalon (small tetrapeptide, 390 Da, some nasal research)
✓ Topical (skin-local only, not systemic): GHK-Cu serums and creams (cosmetic, skin-surface only)
✗ Do not exist or not validated: Oral Tirzepatide — does not exist in any approved form as of May 2026 — products sold online are unapproved and dangerous) · Generic sublingual peptide drops · BPC-157 standard nasal spray (no human research, quality control issues)
Section 2b — Root-cause thesis
The one idea this whole protocol is built around
Hormone Signaling is the upstream driver in this profile — the area you flagged as your primary focus, so the plan puts its foundation there, addressing the signals that pull energy, drive, body composition, and recovery out of balance at the source.
The matched categories are several expressions of the same picture. Stabilizing the anchor is the foundation; energy, vitality, and the supporting areas build from it. The plan is sequenced so the foundation goes first and everything else builds on it.
Section 3 — Compound educational overview
Compounds most commonly discussed for your categories
CJC-1295 + Ipamorelin
ResearchModerate onset
Weight Loss / Body Composition🌙 Bedtime · fasted
GH-releasing hormone analogue (CJC-1295) paired with a GH secretagogue (Ipamorelin). Discussed for sleep quality, lean-tissue support, recovery, and GH-pathway signaling. Bedtime, fasted timing aligns with natural GH release.
GHK-Cu
ResearchSlow onset
Skin / AestheticFlexible timing
Copper peptide studied for collagen stimulation, wound healing, skin repair, and hair follicle support. Gradual onset — typically first noticed at 4–8 weeks with consistent use.
MOTS-c
ResearchSlow onset
Weight Loss / Body Composition☀ Morning · own syringe
Mitochondrial-derived peptide studied for cellular energy regulation, metabolic support, and exercise performance. Morning timing aligns with natural metabolic rhythm.
SS-31
ResearchSlow onset
Energy / Mitochondrial☀ Morning · own syringe
Mitochondrial membrane-targeted peptide (cardiolipin) studied for cellular energy and membrane integrity. The second step of the mitochondrial arc.
DSIP
ResearchFast onset
Energy / Mitochondrial🌙 ~30 min before sleep
Delta sleep-inducing peptide studied for sleep onset and depth; deeper, more consolidated sleep supports recovery, glucose regulation, and GH release.
NAD+
ResearchSlow onset
Energy / Mitochondrial☀ Morning · own syringe
Nicotinamide adenine dinucleotide — a cellular coenzyme central to mitochondrial energy production, sirtuin and DNA-repair pathways, and metabolic function; routinely used alongside peptides for energy and longevity support.
PT-141
ResearchFast onset
Libido / Sexual WellnessAs needed
Melanocortin-receptor agonist (MC3R/MC4R) studied for sexual desire and arousal; as-needed dosing 1–2 hours before, not daily.
Oxytocin
ResearchFast onset
Libido / Sexual WellnessAs needed
Neuropeptide studied for connection, mood, and the quality side of intimacy; pairs with PT-141, as-needed.
Tirzepatide
ResearchFast onset
Weight Loss / Body CompositionOnce weekly · separate syringe
Dual GLP-1 / GIP receptor agonist studied for appetite regulation, glucose control, and weight management; once-weekly titration.
BPC-157
ResearchModerate onset
Weight Loss / Body CompositionFlexible timing
Body-protective compound studied for gut-lining integrity, tendon and ligament repair, and tissue and flora support. In this plan it is introduced alongside the GLP-1 to support gut tolerance.
AOD-9604
ResearchModerate onset
Weight Loss / Body Composition☀ Morning
Growth-hormone fragment studied for targeted fat metabolism (lipolysis) without the broader effects of full GH; morning preferred, fasted.
Thymosin Alpha-1
ResearchSlow onset
—Flexible · course-based
Thymic peptide studied for immune modulation, resilience, and inflammatory balance. Effects are cumulative — typically 4–12 weeks of consistent use before meaningful differences are reported.
Epithalon 50mg
ResearchSlow onset
—Flexible · course-based
Primary mechanism: Activates telomerase — the enzyme responsible for maintaining and elongating telomeres. Telomeres are the protective DNA caps at chromosome ends that shorten with each cell division.
Section 4 — Protocol dose reference
Educational dose framework, reconstitution, and unit reference
On dosing frequency — one approach, confirm with your clinician. The frequencies and schedules in this report reflect one clinical approach. The same compounds are discussed at different frequencies across the peptide community, and there is no single "correct" schedule. Use what's here as a starting framework and confirm the frequency that's right for you with your clinician.
On reconstitution — one standard, not the only one. The dilutions shown for each peptide — the vial size paired with the BAC water volume — reflect one common reconstitution standard. Many other dilution ratios are used throughout the peptide community; a different diluent volume changes the units you draw per dose, not the dose itself. Use what's here as a reference and confirm your reconstitution approach with your clinician.
Educational reference — read before using this section
All dose ranges, reconstitution examples, syringe unit calculations, timing references, and frequency notes below are based on general educational observations from biohacking communities, peer discussions, and publicly available research references. Units are rounded to the nearest practical syringe mark. All dosing and protocol decisions should be evaluated by a licensed pharmacist or clinician before use. Peptides and related products are strictly for laboratory research use and are not intended for human consumption, diagnosis, treatment, or any medical purpose.
CJC-1295
ResearchHormone Signaling
Vial / Diluent
5 mg / in your report BAC water
in your report
Dose range
in your report
17–50 uses per vial
Frequency
5 days on / 2 days off
bedtime fasted 90 min before AND after dosing
Supported average: 250 mcg = in your report
Syringe unit reference — in your report / in your report BAC water
💉 Wk 1 (tolerance): 100 mcg = in your report · Wk 2+ (established): in your report = in your report
⚠ Fasting required — not optional. GH peptides taken without fasting have drastically reduced efficacy. Insulin suppresses GH release directly. Fasted 90 minutes before AND 90 minutes after dosing. No carbs or protein before injection.
⏰ Timing: 5 nights on / 2 nights off · bedtime fasted 90 min before AND after dosing.
About CJC-1295: Growth hormone-releasing hormone analogue studied for GH pulse stimulation, lean tissue support, sleep quality, and recovery. Works by stimulating the pituitary to release growth hormone naturally. Effects are cumulative — sleep quality improvements are often reported first, with body composition changes typically requiring 4–8 weeks of consistent use.
CJC-1295 and Ipamorelin are drawn into one syringe immediately before injection — mixed only at the time of use, never pre-mixed in a vial.
⚠ Safety & Side Effects
If you take more than the listed dose: Above-range or too-frequent dosing amplifies growth-hormone excess — more fluid retention (puffy hands and feet), joint aches, carpal-tunnel-type wrist numbness or tingling, and headache — and can push fasting glucose and IGF-1 upward. More is not better: higher doses add side effects, not benefit. Persistently elevated IGF-1 is a reason to reduce or hold.
Stop and seek medical care if: Signs of an allergic reaction — hives, swelling of the face, lips, or tongue, throat tightness, or trouble breathing — are an emergency; stop and get care. Also seek care for a severe or persistent headache, vision changes, or new numbness that does not resolve.
Commonly reported / expected: Injection-site redness, itching, or a small bump; facial flushing; mild water retention; tingling in the hands; and drowsiness at bedtime. Most are mild, dose-dependent, and settle over the first 2–4 weeks.
Clinician monitoring: Baseline and periodic IGF-1 and fasting glucose.
Educational summary from published prescribing and research literature — not a substitute for your treating clinician’s guidance.
Ipamorelin
ResearchHormone Signaling
Vial / Diluent
5 mg / in your report BAC water
in your report
Dose range
in your report
10–50 uses per vial
Frequency
5 days on / 2 days off
Supported average: 250 mcg = in your report
Syringe unit reference — in your report / in your report BAC water
💉 Wk 1 (tolerance): 100 mcg = in your report · Wk 2+ (established): in your report = in your report
⏰ Timing: Paired with its GHRH partner's schedule (CJC-1295, or Tesamorelin for visceral fat) when stacked.
About Ipamorelin: Selective growth hormone secretagogue studied for GH release, lean muscle support, recovery, and sleep quality. Known for a clean GH pulse with minimal effect on cortisol or prolactin compared to other secretagogues. Most commonly paired with CJC-1295 for a synergistic GH stack. Onset typically 2–6 weeks with consistent bedtime use.
CJC-1295 and Ipamorelin are drawn into one syringe immediately before injection — mixed only at the time of use, never pre-mixed in a vial.
⚠ Safety & Side Effects
If you take more than the listed dose: Taking more than the listed dose can trigger a stronger growth-hormone surge with nausea, stomach ache, or loose stools, plus more water retention and headache; it does not increase benefit. Strong ghrelin-receptor stimulation can also cause brief lightheadedness.
Stop and seek medical care if: Allergic reaction — hives, swelling of the face, lips, or throat, throat tightness, or difficulty breathing — stop and get emergency care.
Commonly reported / expected: Injection-site reaction, mild headache in the first week, slight puffiness from water retention, tingling in the extremities, and welcome bedtime drowsiness. Among the more selective growth peptides — usually does not raise appetite, cortisol, or prolactin at standard doses.
Clinician monitoring: IGF-1 periodically when combined with a GHRH.
Educational summary from published prescribing and research literature — not a substitute for your treating clinician’s guidance.
GHK-Cu
ResearchSkin / Aesthetic
Vial / Diluent
50 mg / in your report BAC water
~in your report
Dose range
in your report
25–50 uses per vial
Frequency
5 days on / 2 days off
flexible timing · no fasting required
Supported average: 2,000 mcg → in your report
Syringe unit reference — in your report / in your report BAC water
💉 Wk 1 (tolerance): 1,000 mcg → in your report · Wk 2+ (standard): in your report → in your report
⏰ Timing: 5 on / 2 off · flexible timing · no fasting required.
About GHK-Cu: Copper peptide studied for collagen stimulation, wound healing, skin repair, and hair follicle support. Gradual onset — typically first noticed at 4–8 weeks with consistent use.
Solo syringe always · units rounded down for ease.
⚠ Safety & Side Effects
If you take more than the listed dose: Because it carries copper, repeated above-range dosing risks copper overload — nausea, a metallic taste, headache, fatigue, or (rarely, with chronic excess) liver strain. Avoid entirely in Wilson's disease or other copper-handling disorders. Larger or more frequent doses do not speed results.
Stop and seek medical care if: Allergic reaction — hives, swelling of the face or throat, throat tightness, trouble breathing — stop and seek care.
Commonly reported / expected: Injection-site redness, itching, stinging, or a small bump; occasional lightheadedness. Generally well tolerated at standard subcutaneous doses.
Clinician monitoring: Consider copper / ceruloplasmin if used at high dose or long term.
Educational summary from published prescribing and research literature — not a substitute for your treating clinician’s guidance.
MOTS-c
ResearchEnergy / Mitochondrial
Vial / Diluent
10 mg / in your report BAC water
in your report
Dose range
in your report/week (2.5–5 mg per dose)
2–4 uses per vial (~1–2 weeks depending on dose)
Frequency
2× weekly
morning preferred, no fasting
Supported average:in your report = in your report
Syringe unit reference — in your report / 1 mL BAC water
💉 in your report = in your report · in your report = 50 units
⏰ Timing: 2× weekly (Mon/Thu or Tue/Fri) · morning preferred, no fasting.
About MOTS-c: Mitochondrial-derived peptide studied for cellular energy regulation, metabolic support, and exercise performance. Morning timing aligns with natural metabolic rhythm.
Separate syringe always.
⚠ Safety & Side Effects
If you take more than the listed dose: Above-range dosing has no proven added benefit and can bring on transient fatigue, flushing, or GI upset. Because it acts on metabolism and insulin sensitivity, larger doses may shift blood sugar — of note if you are diabetic or fasting.
Stop and seek medical care if: Allergic reaction (hives, swelling of the face or throat, throat tightness, trouble breathing) — get emergency care.
Commonly reported / expected: Injection-site reaction, occasional flushing or warmth, mild fatigue, and mild GI upset. Human safety data are limited; generally well tolerated in available reports.
Educational summary from published prescribing and research literature — not a substitute for your treating clinician’s guidance.
SS-31
ResearchEnergy / Mitochondrial
Vial / Diluent
in your report / in your report BAC water
in your report
Dose range
2.5 mg
4 uses per vial
Frequency
2× weekly
AM or pre-workout preferred
Supported average:in your report = in your report
Syringe unit reference — in your report / 1 mL BAC water
💉 in your report = in your report
⏰ Timing: 2× weekly · AM or pre-workout preferred.
About SS-31: Mitochondrial membrane-targeted peptide (cardiolipin) studied for cellular energy and membrane integrity. The second step of the mitochondrial arc.
Separate syringe always.
⚠ Safety & Side Effects
If you take more than the listed dose: Above-range dosing offers no established added benefit and mainly increases injection-site reactions and possible headache or GI upset. Do not self-escalate.
Stop and seek medical care if: Allergic reaction (hives, swelling, throat tightness, trouble breathing) — get emergency care.
Commonly reported / expected: Injection-site redness, itching, or bruising; occasional headache; and mild GI upset. Well tolerated in clinical study at standard doses; broader long-term data are still accumulating.
Educational summary from published prescribing and research literature — not a substitute for your treating clinician’s guidance.
DSIP
ResearchEnergy / Mitochondrial
Vial / Diluent
in your report / 2 mL BAC water
in your report
Dose range
in your report
17–50 uses per vial
Frequency
5 days on / 2 days off
start low · daytime or pre-bed
Supported average: 200 mcg = 8u
Syringe unit reference — in your report / 2 mL BAC water
💉 in your report = in your report · in your report = 8u · in your report = in your report
⏰ Timing: 5 days on / 2 days off · start low · daytime or pre-bed.
About DSIP: Delta sleep-inducing peptide studied for sleep onset and depth; deeper, more consolidated sleep supports recovery, glucose regulation, and GH release.
May share a bedtime syringe with compatible peptides — see compatibility reference.
⚠ Safety & Side Effects
If you take more than the listed dose: Above-range dosing does not deepen the benefit and may cause next-day grogginess, headache, or lightheadedness. It is used in short cycles rather than nightly without end.
Stop and seek medical care if: Allergic reaction (facial or throat swelling, throat tightness, trouble breathing) — get emergency care.
Commonly reported / expected: Morning grogginess, mild headache, or injection-site reaction. Generally well tolerated; human safety data are limited.
Educational summary from published prescribing and research literature — not a substitute for your treating clinician’s guidance.
NAD+
ResearchEnergy / Mitochondrial
Vial / Diluent
in your report / 5 mL BAC water
in your report
Dose range
in your report = in your report, or 50 mg = in your report
20 uses per vial (at in your report dosing)
Frequency
in your report 5 days on / 2 days off, or 50u 2× weekly
AM preferred, avoid evening · separate syringe
Supported average:in your report = in your report
Syringe unit reference — in your report / 5 mL BAC water
💉 in your report = in your report · in your report = 50u (use in your report syringe for larger volumes)
⏰ Timing:in your report 5 days on / 2 days off, or in your report 2× weekly · AM preferred, avoid evening · separate syringe.
About NAD+: Nicotinamide adenine dinucleotide — a cellular coenzyme central to mitochondrial energy production, sirtuin and DNA-repair pathways, and metabolic function; routinely used alongside peptides for energy and longevity support.
Separate syringe (larger volume).
⚠ Safety & Side Effects
If you take more than the listed dose: The classic problem is giving the dose TOO FAST or TOO MUCH — flushing or warmth, chest tightness or pressure, nausea, abdominal cramping, headache, and a racing heartbeat. These effects are rate-related and ease when the dose is slowed, split into smaller subcutaneous injections, or paused. Give it slowly; never push a large dose quickly.
Stop and seek medical care if: Allergic reaction (hives, facial swelling, throat tightness, trouble breathing), palpitations that do not settle, or severe chest pressure — stop and seek care. With IV use, vein irritation or phlebitis.
Commonly reported / expected: Flushing, nausea, headache, lightheadedness, mild cramping, and injection-site soreness — mostly mild and short-lived when given slowly. Fasting and staying hydrated before dosing improve tolerance.
Educational summary from published prescribing and research literature — not a substitute for your treating clinician’s guidance.
PT-141
ResearchLibido / Sexual Wellness
Vial / Diluent
10 mg / in your report BAC water
in your report
Dose range
in your report
10–20 uses per vial
Frequency
as-needed pre-event (max 1× per 24h)
never daily
Supported average: Start at 250 mcg = 5u
Syringe unit reference — 10 mg / in your report BAC water
💉 in your report = in your report · 500 mcg = in your report · in your report = in your report (max)
⏰ Timing: As-needed only · never daily.
About PT-141: Melanocortin-receptor agonist (MC3R/MC4R) studied for sexual desire and arousal; as-needed dosing 1–2 hours before, not daily.
titrate up as tolerated to 500 mcg = in your report · Separate syringe always.
⚠ Safety & Side Effects
If you take more than the listed dose: Do NOT exceed one dose in 24 hours or more than 8 doses per month. Above-range or too-frequent dosing worsens nausea (sometimes needing anti-nausea medicine), raises blood pressure more, and — with repeated excess — can darken the skin of the face, gums, or breasts (focal hyperpigmentation), which may not fully reverse. A prolonged, painful erection lasting over 4 hours is a medical emergency.
Stop and seek medical care if: Blood pressure spiking (severe headache, dizziness, blurred vision), an erection lasting more than 4 hours, or an allergic reaction (facial or throat swelling, throat tightness, trouble breathing) — seek emergency care. Not for people with uncontrolled high blood pressure or known cardiovascular disease.
Commonly reported / expected: Nausea (very common, roughly 40 percent, and can last 2 or more hours), flushing, headache, and injection-site reaction; a small, temporary rise in blood pressure with a slight drop in heart rate that peaks a few hours after dosing.
Clinician monitoring: Blood pressure; caution with cardiovascular disease.
Educational summary from published prescribing and research literature — not a substitute for your treating clinician’s guidance.
Oxytocin
ResearchLibido / Sexual Wellness
Vial / Diluent
in your report / in your report BAC water
1,000 mcg/mL
Dose range
in your report
~30 uses per vial
Frequency
as-needed
timing flexible
Supported average: 50 mcg = 5u
Syringe unit reference — in your report / in your report BAC water
💉 50 mcg = in your report
⏰ Timing: As-needed · timing flexible.
About Oxytocin: Neuropeptide studied for connection, mood, and the quality side of intimacy; pairs with PT-141, as-needed.
Separate syringe.
⚠ Safety & Side Effects
If you take more than the listed dose: TAKING MORE THAN THE LISTED DOSE is the specific risk this closes — it commonly causes abdominal or uterine cramping and GI upset (nausea, vomiting), along with flushing and headache. Because oxytocin acts like the water-retaining hormone vasopressin, a large or repeated dose TOGETHER WITH a lot of fluid can cause water intoxication and low blood sodium (hyponatremia): confusion, lethargy, and in severe cases seizures. If you took extra and have strong cramps, nausea, or feel confused or foggy, stop and contact your clinician. Effects are short-lived once dosing stops.
Stop and seek medical care if: Severe or sustained cramping, chest tightness, fainting, confusion, or an allergic reaction (facial or throat swelling, throat tightness, trouble breathing) — seek emergency care. Contraindicated in pregnancy.
Commonly reported / expected: Mild flushing, nausea, or headache at standard doses.
Clinician monitoring: Avoid heavy fluid loading around dosing; watch sodium if used frequently at higher doses.
Educational summary from published prescribing and research literature — not a substitute for your treating clinician’s guidance.
Tirzepatide
ResearchWeight Loss / Body Composition
Dose / titration
in your report
mg titration = the dose (manufacturer pen)
Frequency
Once weekly
once weekly · titrated upward in in your report increments
Reference
GLP-1 Dosing Reference
Reference_Tables/GLP1_Dosing_Reference.html
Framing: the mg titration is the manufacturer dosing; the units math applies ONLY to research-grade reconstituted material and must always be labeled as such — never present units as "the dose."
First-week tolerance split (new to / switching GLP-1)
About Tirzepatide: Dual GLP-1 / GIP receptor agonist studied for appetite regulation, glucose control, and weight management; once-weekly titration.
Separate syringe always. Once weekly only — never daily or 5-on/2-off.
⚠ Safety & Side Effects
If you take more than the listed dose: Above-range or double dosing (do NOT double up to make up a missed dose, and do not use a higher-than-prescribed concentration) causes intractable vomiting, severe abdominal pain, persistent diarrhea, rapid dehydration, dizziness, and possible low blood sugar (mainly alongside insulin or a sulfonylurea). Because it stays active about 5 days and peaks 24–48 hours after dosing, symptoms can persist for DAYS; there is no antidote — care is supportive.
Stop and seek medical care if: Signs of pancreatitis (severe abdominal pain to the back), a gallbladder attack, acute kidney injury from dehydration, severe low blood sugar (confusion, loss of consciousness), chest pain or severe palpitations, or an allergic reaction — seek emergency care. Boxed thyroid-tumor warning: avoid with a personal or family history of medullary thyroid cancer or MEN 2.
Commonly reported / expected: Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, and injection-site reaction, mainly during escalation.
Clinician monitoring: Baseline and periodic kidney function, lipase, and glucose; slow titration.
Educational summary from published prescribing and research literature — not a substitute for your treating clinician’s guidance.
BPC-157
ResearchWeight Loss / Body Composition
Vial / Diluent
5 mg / in your report BAC water
in your report
Dose range
in your report
10–20 uses per vial
Frequency
5 days on / 2 days off
4–6 week cycles
Supported average: 250 mcg = in your report
Syringe unit reference — in your report / in your report BAC water
💉 250 mcg = in your report · in your report = in your report
⏰ Timing: AM after workout (AM preferred if no workout) · 4–6 week cycles.
About BPC-157: Body-protective compound studied for gut-lining integrity, tendon and ligament repair, and tissue and flora support. In this plan it is introduced alongside the GLP-1 to support gut tolerance.
Healing stack with TB-500 + KPV (may share); separate from other compounds.
⚠ Safety & Side Effects
If you take more than the listed dose: Human dose-ranging data are limited. Taking more than the listed amount has not been shown to add benefit and mainly increases the chance of nausea, dizziness, headache, and injection-site irritation. Escalate only under a clinician.
Stop and seek medical care if: Allergic reaction (hives, swelling of the face, lips, or throat, throat tightness, trouble breathing) — get emergency care. Stop for any severe or persistent reaction.
Commonly reported / expected: Mild fatigue or dizziness, temporary headache, mild transient nausea, and injection-site irritation — usually resolving within 24–72 hours. Generally well tolerated in available reports; long-term human safety data are limited. Prohibited by WADA for competitive athletes.
Educational summary from published prescribing and research literature — not a substitute for your treating clinician’s guidance.
AOD-9604
ResearchWeight Loss / Body Composition
Vial / Diluent
5 mg / in your report BAC water
~in your report
Dose range
in your report
10–20 uses per vial
Frequency
5 days on / 2 days off
AM fasted, 30–45 min before food
Supported average: 250 mcg = in your report
Syringe unit reference — in your report / in your report BAC water
💉 250 mcg = in your report · in your report = in your report
⏰ Timing: 5 days on / 2 days off · AM fasted, 30–45 min before food.
About AOD-9604: Growth-hormone fragment studied for targeted fat metabolism (lipolysis) without the broader effects of full GH; morning preferred, fasted.
Separate syringe.
⚠ Safety & Side Effects
If you take more than the listed dose: Above-range dosing has no established added benefit and mainly increases injection-site reaction, mild headache, or dizziness. Unlike full growth peptides it is not expected to raise IGF-1 or blood sugar meaningfully, but do not self-escalate.
Stop and seek medical care if: Allergic reaction (hives, swelling of the face or throat, throat tightness, trouble breathing) — get emergency care.
Commonly reported / expected: Injection-site reaction and occasional mild headache or dizziness; generally well tolerated. Human safety data are limited.
Educational summary from published prescribing and research literature — not a substitute for your treating clinician’s guidance.
Thymosin Alpha-1
Research—
Vial / Diluent
10 mg / in your report BAC water
in your report
Dose range
in your report
10 injections per vial (Option A) / 6 per course (Option B)
Frequency
course-based: 10 consecutive days, or 2× weekly × 3 weeks
repeat every 3 months
Supported average: 1,000 mcg = in your report (Option A)
Syringe unit reference — in your report / in your report BAC water
💉 1,000 mcg = in your report (Option A) · in your report = in your report (Option B)
⏰ Timing: Course-based: 10 consecutive days, or 2× weekly × 3 weeks · repeat every 3 months.
About Thymosin Alpha-1: Thymic peptide studied for immune modulation, resilience, and inflammatory balance. Effects are cumulative — typically 4–12 weeks of consistent use before meaningful differences are reported.
Pairs with most compatible same-time compounds — see compatibility reference.
⚠ Safety & Side Effects
If you take more than the listed dose: Above-range dosing has no established added benefit and mainly increases injection-site reaction and possible fatigue or a flu-like feeling. Because it modulates immunity, discuss any escalation with a clinician, especially with an autoimmune condition.
Stop and seek medical care if: Allergic reaction (hives, swelling, throat tightness, trouble breathing) — get emergency care. Stop for any severe reaction.
Commonly reported / expected: Injection-site redness or discomfort, transient fatigue, or mild flu-like symptoms; generally well tolerated.
Educational summary from published prescribing and research literature — not a substitute for your treating clinician’s guidance.
Epithalon 50mg
Research—
Vial / Diluent
50 mg / in your report BAC water
in your report
Dose range
in your report
10 injections per vial = 1 complete course
Frequency
one dose per day × 10-day course
repeat every 3 months
Supported average: 5 mg = 20u
Syringe unit reference — 50 mg / in your report BAC water
💉 in your report = in your report (each dose)
⏰ Timing: 10 consecutive days injections · repeat every 3 months.
About Epithalon 50mg:
Separate syringe always.
⚠ Safety & Side Effects
If you take more than the listed dose: Human dose data are limited. More-than-listed dosing has no proven added benefit and mainly increases injection-site reaction or mild lightheadedness. Because it activates telomerase, it is avoided in active cancer; do not self-escalate.
Stop and seek medical care if: Allergic reaction (hives, swelling, throat tightness, trouble breathing) — get emergency care.
Commonly reported / expected: Injection-site reaction and occasional drowsiness (it is often taken at bedtime); generally well tolerated in short courses. Long-term human safety data are limited.
Educational summary from published prescribing and research literature — not a substitute for your treating clinician’s guidance.
Protocol reference — your compounds
Compound
Vial + Diluent
Dose
Average dose
Frequency
Timing
Fasting
Syringe
CJC-1295
5 mg + yours BAC
yours
yours = 10u
5 days on / 2 days off
Bedtime, fasted
Yes · 90 min
Pairs (CJC+Ipa)
Ipamorelin
yours + yours BAC
yours
250 mcg = yours
5 days on / 2 days off
Bedtime, fasted
Yes · 90 min
Pairs (CJC+Ipa)
GHK-Cu
yours + yours BAC
1,000–2,000 mcg
yours → yours
5 days on / 2 days off
Flexible
Preferred
⚠ Separate
MOTS-c
yours + 1 mL BAC
yours/week (yours per dose)
yours = 25u
2× weekly
Morning
Preferred
⚠ Separate
SS-31
yours + yours BAC
yours
2.5 mg = yours
2× weekly
Morning
No
⚠ Separate
DSIP
5 mg + 2 mL BAC
100–300 mcg
200 mcg = 8u
5 days on / 2 days off
Pre-bed
No
Combinable
NAD+
yours + yours BAC
25 mg = yours, or yours = yours
25 mg = yours
yours 5 days on / 2 days off, or yours 2× weekly
Morning
No
⚠ Separate
PT-141
10 mg + 2 mL BAC
250–1,000 mcg
Start at 250 mcg = 5u
as-needed pre-event (max 1× per 24h)
As-needed
No
⚠ Separate
Oxytocin
2 mg + yours BAC
yours
yours = 5u
as-needed
As-needed
No
⚠ Separate
Tirzepatide
Manufacturer pen
yours
mg titration = the dose
Once weekly
Same day each week
No
⚠ Separate
BPC-157
yours + yours BAC
250–500 mcg
yours = yours
5 days on / 2 days off
Flexible
No
Combinable
AOD-9604
yours + 3 mL BAC
yours
yours = yours
5 days on / 2 days off
Morning
Preferred
Combinable
Thymosin Alpha-1
10 mg + yours BAC
yours
yours = 10u (Option A)
course-based: 10 consecutive days, or 2× weekly × 3 weeks
Course-based
No
Combinable
Epithalon 50mg
50 mg + 2 mL BAC
5 mg
5 mg = 20u
one dose per day × 10-day course
Course-based
No
⚠ Separate
Never freeze reconstituted peptides. Store front of fridge. | GH peptides (CJC-1295, Ipamorelin) — fasting is NOT optional. Efficacy drastically reduced without it. Fasted 90 min before AND 90 min after. | GLP-1 nausea protocol: half dose Monday → remaining half Thursday → full dose every Monday from week 2.
Section 4b — Your 90-day cycle
How your compounds are sequenced across 90 days
Your roster is introduced in phases, not all at once — the locked introduction ramp (Establish → Build → Complete). Each phase is a coherent stopping point: if you and your clinician choose to pause after any month, the plan still holds together.
Weeks 1–4
Establish
CJC-1295 + Ipamorelin
GHK-Cu
MOTS-c
SS-31
PT-141
Tirzepatide
BPC-157
Weeks 5–8
Build
DSIP
NAD+
Weeks 9–12
Complete
Oxytocin
AOD-9604
Clinician-paced additions (beyond the base ceiling):
Thymosin Alpha-1
Epithalon 50mg
These sit on top of the base ramp and are introduced at your clinician’s discretion at consult.
GH-axis continuity and baseline labs (90-day)
How the GH-axis is cycled for you
GH-axis cadence. At age 48 the GH-axis (CJC-1295 + Ipamorelin) runs continuously across the 90 days — no 90-on/30-off macro break, with the weekly 5-on / 2-off rhythm and bedtime, fasted dosing throughout. Because the GH-axis can nudge glucose upward while the GLP-1 lowers it, a baseline pairing of IGF-1 and fasting glucose is noted for your clinician so continuous dosing can be monitored on protocol.
Syringe compatibility reference
Mix only immediately before injection — never pre-mix in a vial or leave a loaded syringe to sit. Everything here is subcutaneous, same route. The groups below are one commonly used compatibility reference — other combining protocols are discussed across peptide forums and communities, and there is no single "correct" grouping. Your clinician confirms what applies to your protocol.
✓ Nighttime / bedtime — commonly combined
CJC-1295, Ipamorelin, DSIP, Thymosin Alpha-1
✓ Morning / daytime — commonly combined
AOD-9604, BPC-157, NAD+ (caution)
⚠ GHK-Cu — keep it stand-alone (client’s discretion). Some clinics combine it with the healing stack, but its copper content and pH sensitivity make a separate syringe the conservative standard — and injecting it alone means that if a skin reaction or side effect appears, you know exactly which compound caused it.
✗ Keep separate — its own syringe
Tirzepatide and other GLP-1 / GIP agonists, PT-141, Oxytocin, GHK-Cu, MOTS-c, SS-31, Epithalon 50mg, and any acetic-acid–reconstituted peptide.
Key rules
• Mix immediately before injection
• Plain BAC water — no saline (NaCl)
• Keep total volume low (≈in your report)
• Draw the larger-volume peptide first
• Check for cloudiness — discard if present
• All subcutaneous (same route)
Syringe compatibility disclaimer
Compatibility information is based on community consensus, educational sources, and general biohacking references. Applies to immediate use only — not long-term vial storage. All mixing decisions should be reviewed with a licensed pharmacist or clinician. Source: Reddit r/Peptides, r/BioHackingGuide, LinkedIn peptide clinicians, 2025–2026 research references.
Section 5 — Vial and reconstitution concepts
Understanding vials, BAC water, and supply planning
What is reconstitution?
Most research peptides are supplied as a lyophilized (freeze-dried) powder. Before use, the powder is combined with bacteriostatic water (BAC water) to create a liquid solution. The amount of BAC water added determines the concentration. Your professional or pharmacy provides specific reconstitution instructions.
What is BAC water?
Bacteriostatic water is sterile water containing benzyl alcohol, which preserves the solution after the vial is opened. It is not the same as sterile water for injection. The correct diluent must be confirmed with your professional or pharmacy.
Storage requirements
Lyophilized powder is stored refrigerated at 2–8°C and protected from light. Once reconstituted, solutions are generally used within 28–30 days and kept refrigerated. Never freeze a reconstituted peptide solution — freezing after reconstitution can degrade the compound and compromise the entire vial. Store toward the front of the refrigerator, not the back — the back of most refrigerators runs colder and may approach freezing temperatures, which can damage the solution. Specific storage requirements vary by compound — confirm with your source or professional.
Section 6 — AM / PM organization
General timing framework for your matched compounds
☀ Morning — commonly referenced
GHK-Cu — Flexible timing
MOTS-c — ☀ Morning · own syringe
SS-31 — ☀ Morning · own syringe
NAD+ — ☀ Morning · own syringe
BPC-157 — Flexible timing
AOD-9604 — ☀ Morning
🌙 Evening / Bedtime — commonly referenced
CJC-1295 + Ipamorelin — 🌙 Bedtime · fasted
DSIP — 🌙 ~30 min before sleep
Once-weekly / as-needed / course compounds are scheduled separately (see Section 4).
Timing is educational context only. Your licensed professional confirms appropriate timing, frequency, and sequence for your specific situation.
Section 7 — Fasting considerations
How food timing relates to specific compounds
⚠ GH Peptides — Fasting is NOT optional. Efficacy is drastically reduced without it.
The following GH-pathway peptides MUST be taken in a fully fasted state: CJC-1295, Ipamorelin, Tesamorelin. Insulin from recent food intake actively suppresses GH release — directly counteracting the purpose of these compounds. Fasted 90 minutes before AND 90 minutes after dosing. No carbohydrates or protein before injection. This is a requirement, not a preference. Strict adherence to fasted timing is critical.
MOTS-c — fasted or light-fasted state preferred
Fasted or light-fasted state preferred for enhanced metabolic effect. Morning use in a fasted or lightly fasted state is commonly referenced for mitochondrial and metabolic compounds. Some discussions reference pre-exercise timing for enhanced metabolic effect. Confirm timing approach with your professional.
Tirzepatide (and all GLP-1 compounds) — no strict fasting requirement
GLP-1 pathway compounds do not require a fasted state. Typically administered once weekly unless otherwise directed. No fasting required — taking with a light meal or on an empty stomach may help manage initial GI discomfort at the start of a protocol.
Tolerance protocol for nausea (recommended for all GLP-1 compounds): To test tolerance and reduce the risk of nausea at initiation, split the first week: take half the dose on Monday and the remaining half on Thursday. From week 2, take the full dose every Monday. This split approach allows the body to acclimate before committing to a full weekly dose. Do not apply 5-on/2-off logic to any GLP-1 compound — weekly dosing only.
GHK-Cu, Semax, Selank, Thymosin Alpha-1 — no fasting requirement
These compounds do not have commonly referenced fasting requirements. They can generally be used with or without food. Confirm any specific timing preferences with your professional based on your overall schedule.
Section 8 — Timeline expectations by compound
When effects are typically first reported
CJC-1295 + IpamorelinModerate
Typical onset: 2–6 weeks (sleep) · recomposition up to 6 months
Typically reported after a few weeks of consistent use.
GHK-CuSlow
Typical onset: 4–12 weeks (cumulative)
Cumulative and slow-building; rarely judged fairly in under 4–8 weeks.
MOTS-cSlow
Typical onset: 4–12 weeks (cumulative)
Cumulative and slow-building; rarely judged fairly in under 4–8 weeks.
SS-31Slow
Typical onset: 4–12 weeks (cumulative)
Cumulative and slow-building; rarely judged fairly in under 4–8 weeks.
DSIPFast
Typical onset: Days to 1–2 weeks
Often among the earliest-reported effects; individual sensitivity varies.
NAD+Slow
Typical onset: 4–12 weeks (cumulative)
Cumulative and slow-building; rarely judged fairly in under 4–8 weeks.
PT-141Fast
Typical onset: Days to 1–2 weeks
Often among the earliest-reported effects; individual sensitivity varies.
OxytocinFast
Typical onset: Days to 1–2 weeks
Often among the earliest-reported effects; individual sensitivity varies.
TirzepatideFast
Typical onset: Days to 1–2 weeks
Often among the earliest-reported effects; individual sensitivity varies.
BPC-157Moderate
Typical onset: 2–6 weeks
Typically reported after a few weeks of consistent use.
AOD-9604Moderate
Typical onset: 2–6 weeks
Typically reported after a few weeks of consistent use.
Thymosin Alpha-1Slow
Typical onset: 4–12 weeks (cumulative)
Cumulative and slow-building; rarely judged fairly in under 4–8 weeks.
Epithalon 50mgSlow
Typical onset: 4–12 weeks (cumulative)
Cumulative and slow-building; rarely judged fairly in under 4–8 weeks.
Individual results vary significantly. These timelines are general educational observations only — not guaranteed outcomes.
Section 8b — Protecting muscle and bone during weight loss
Losing weight fast is not only fat — protect what you don't want to lose
Rapid weight loss — the kind a GLP-1 pathway compound like Tirzepatide can produce — is not all fat. A meaningful share of what comes off can be lean muscle, and over time, bone. The compound does the fat loss; the steps below are what keep the weight you lose to the weight you actually want to lose.
Why this matters. Clinical trials of GLP-1 / GIP compounds (Tirzepatide, Semaglutide) report that roughly 25–40% of total weight lost can be lean mass rather than fat. That is a better ratio than older rapid-weight-loss methods — but it still means real muscle loss, and it matters most for older adults, athletic individuals, and anyone already metabolically vulnerable.
1
Protein — the single most important lever
Target 1.0–1.2 g of protein per pound of goal body weight (goal weight, not current), spread across at least three meals — roughly 30–50 g each. On a GLP-1, with appetite down, hitting protein is the hardest and most important thing you will do. Your Meal Plan companion is built around this.
2
Resistance training — the signal to keep muscle
Even two full-body resistance sessions per week dramatically reduce lean-mass loss. A GLP-1 without resistance training carries a high muscle-loss risk; a GLP-1 with consistent lifting steers the loss toward fat. Two sessions a week is the floor; three to four is ideal. Your Movement companion lays out the sessions.
3
GH-pathway compounds — already in your protocol
CJC-1295 + Ipamorelin support lean mass through GH / IGF-1 signaling — one reason they sit alongside a weight-loss compound. Creatine monohydrate (3–5 g per day, non-peptide, well documented for preserving lean mass during caloric restriction) is a low-cost addition to discuss with your professional.
Bone density. Significant weight loss can also affect bone density. Adequate calcium, vitamin D, and protein during weight loss are important, and the growth-hormone-pathway compounds in this report have been associated with improved bone turnover markers in research contexts. If you have any history of low bone density, osteopenia, osteoporosis, or a prior fracture, raise it with your professional before beginning — it changes how this protocol should be approached. This is general educational information, not medical advice.
Section 9 — Adherence and consistency guidance
Making your educational framework sustainable
📌
Start narrow — build from there
Beginning with 1–2 compounds allows you and your professional to identify what is working, what needs adjusting, and what to add next. Starting with a full compound list at once makes it difficult to attribute changes — positive or negative — to any single compound.
🔁
What to do if you miss a day
For daily compounds: skip the missed dose and resume the following day. Do not double-dose. For 5-on/2-off compounds: the off days are built in — simply continue your schedule. For weekly compounds like Tirzepatide: follow your prescriber's guidance on what to do if a scheduled dose is missed.
📅
Habit stacking for consistency
Attaching compound use to an existing daily habit — morning coffee, bedtime routine, pre-workout — significantly improves adherence. Set a phone reminder for each compound at its typical timing. Keep a consistent preparation area with supplies organized and accessible.
⚠️
When to pause and check in
Pause use and contact your professional if you experience: unexpected injection site reactions that worsen or spread, systemic symptoms (nausea, dizziness, rash, swelling), mood changes that feel significant or unusual, or any symptom you are uncertain about. Do not self-adjust dose or frequency without professional guidance.
📊
Evaluating results fairly
Do not evaluate the effectiveness of slow-onset compounds like GHK-Cu or Thymosin Alpha-1 within the first 30 days. Skin and immune changes are cumulative. Fast-onset compounds like Semax and Selank may provide quicker feedback. Use the 90-day tracker to observe changes systematically rather than relying on daily impressions.
Section 10 — Budget and supply planning
Mapping your compound list to a monthly supply budget
Your 14-compound list, mapped to a realistic monthly supply budget. Running the full stack at once is the high end; the priority framework below sequences your compounds so you and your professional can decide where to start and what to add as results build. Your GLP-1 (Tirzepatide) is the largest single line and is priced separately through a pharmacy ($150–$350/mo). Cost figures are educational references (Budget Planning Library, May 2026) and vary by source, vial size, and region.
Priority 1 — Highest-impact anchorsStart here
Your primary-category compounds — the GH-axis, mitochondrial, and metabolic anchors that target your top goals. CJC-1295 + Ipamorelin ($100–$170/mo); GHK-Cu (varies by source); MOTS-c ($70–$120/mo); SS-31 ($40–$70/mo); DSIP ($20–$40/mo); NAD+ ($50–$90/mo); Tirzepatide ($150–$350/mo).
Priority 2 — Core supportAdd when ready
Daily support for sleep, energy, recovery, and gut tolerance alongside the GLP-1. BPC-157 ($50–$90/mo); AOD-9604 ($40–$80/mo).
Priority 3 — As-needed & clinician-pacedPhase in later
As-needed and course-based compounds, introduced once the foundation is established. PT-141 ($35–$60, as-needed, may last 2–3 months); Oxytocin (as-needed, low monthly cost); Thymosin Alpha-1 (~$15–$23/mo amortized, one course every 3 months); Epithalon 50mg (~$13–$23/mo amortized, one course every 3 months).
Supplies
Bacteriostatic water and syringes: $15–$40/mo depending on the number of compounds. Compound pricing varies significantly by source, concentration, and region — these are educational estimates only. Always confirm pricing with your professional or pharmacy, and do not source based on price alone; sterility, purity, and certification matter most.
Section 10b — Nutrition & movement frameworks
The non-compound foundation your protocol is built on
Compounds work on top of a foundation, not instead of one. For a metabolic-, energy-, and hormone-led plan, protein-forward nutrition and consistent resistance + recovery movement do much of the work the peptides are there to amplify — lean-tissue support, glucose stability alongside the GLP-1, and sleep quality. Lead the movement guidance with resistance training (the lever that protects lean mass in a deficit); keep hydration up on the GLP-1; vegetable volume is the easiest free win. Two optional companion documents, elected at your consult, carry the detail: a Meal Plan companion (plate and protein frameworks, GLP-1 food guidance, shopping lists) and a Movement companion (resistance and recovery sessions scaled to effort, not weights). Neither is required to begin.
Section 11 — Getting started
A practical orientation for moving forward
1
Know what you're using before you source it
Review every compound in this report before purchasing anything. Understand the dose, the reconstitution, the timing, and the syringe compatibility. If you are working with a knowledgeable professional, share this report with them. If you are self-directing, use this report as your educational foundation — not a shortcut.
2
Establish a bloodwork baseline
Ask your professional which baseline labs are appropriate before beginning — particularly relevant for hormone signaling, immune function, and the GLP-1 pathway given your age and profile.
3
Start with Priority 1 compounds
Begin with your Stage 1 (Establish) compounds: CJC-1295 + Ipamorelin, GHK-Cu, MOTS-c, SS-31, PT-141, Tirzepatide, BPC-157. Confirm your level and starting stage with your clinician at the consult. Use the separate Peptide Schedule Reference Sheet as your daily guide.
4
Track weekly and observe
Use the 90-day tracker below to note energy, sleep, skin quality, and mood each week. Note any side effects or observations. Bring completed notes to your follow-up professional discussion.
Section 12 — 90-day outcome tracker
What to observe and note each month across 90 days
How to use this tracker: At the end of each month, circle a number 1–5 for each area (1 = much worse · 3 = no change · 5 = noticeably better). Use the notes line to record observations, side effects, or questions. This tracker is designed to help you and your professional have a specific, data-informed follow-up conversation.
Month 1Weeks 1–4 · Establish
Note baseline energy, sleep, glucose/appetite, and tolerance as the foundation compounds are introduced.
Energy / Fatigue
12345
Notes / observations
Sleep Quality
12345
Notes / observations
Glucose / Appetite
12345
Notes / observations
Mood / Clarity
12345
Notes / observations
Month 2Weeks 5–8 · Build
Note recovery, drive, and tolerance of the Stage 2 additions. Stage review with your clinician at Week 8.
Energy / Fatigue
12345
Notes / observations
Sleep Quality
12345
Notes / observations
Glucose / Appetite
12345
Notes / observations
Mood / Clarity
12345
Notes / observations
Month 3Weeks 9–12 · Complete
The 90-day review — note what improved, what to continue, and what to discuss with your clinician at the next consult.
Energy / Fatigue
12345
Notes / observations
Sleep Quality
12345
Notes / observations
Glucose / Appetite
12345
Notes / observations
Mood / Clarity
12345
Notes / observations
Storage & refrigeration reference
Storage & Handling — Non-Negotiable Rules
Storage & Handling — Non-Negotiable Rules
Never Freeze Reconstituted
Refrigerator only — never the freezer. Freezing degrades peptides after reconstitution.
Refrigerator Position
Store toward the front of the shelf — back of most refrigerators approaches freezing.
Lyophilized (Powder)
Refrigerated at 2–8°C, away from light and heat, until reconstituted.
Reconstituted Vials
Use within 28–30 days. Keep refrigerated. Never at room temperature for extended periods.
Label Everything
Label every vial with compound name + reconstitution date. Memory is not reliable for this.
BAC Water Standard
Pharmaceutical-grade from licensed compounding pharmacy or verified research supplier only.
PeptideReport.ai · 90-Day Comprehensive ReportPR-90D-SAMPLE-2026 · July 8, 2026
Print & hang · educational reference · confirm every value with your clinician before you begin
⚠ Read first — the unit counts assume the reconstitution shown for each compound. A “unit” is on a standard insulin syringe (100 units = 1 mL). The draw amounts below are calculated for the exact vial size + BAC water volume listed in each row. If your vial size or your BAC water volume is different, your unit count is different — do not use these numbers until your clinician confirms them against the vials you actually have.
* = own syringe, never co-mixed (SS-31, MOTS-c, GHK-Cu, NAD+). FAST 90m = no food 90 min before & after the dose; no carbohydrates or protein.
Tirzepatide is titrated — it steps up over months, it is not a fixed weekly dose. Stay at each step at least 4 weeks; only move up if your GI tolerance allows. Never increase the dose during a week of active nausea or GI distress.
Stage
Weekly dose
Draw
Notes
Month 1 (Wk 1–4)
yours
25u
yours vial + yours BAC
Month 2 (Wk 5–8)
yours
25u
yours vial + yours BAC
Month 3 (Wk 9–12)
yours
target
per response / GI tolerance
Month 4
10 mg
target
each step held ≥ 4 weeks
Month 5
yours
target
not all users need the final step
Your 90 days — what to take each month
One print-and-hang schedule per month. Compounds layer in as the plan builds (Establish → Build → Complete); Tirzepatide steps up each month. Bold = units to draw at that step. * = own syringe. new = introduced that month.
Month 1 Weeks 1–4 · Establish
When
Mon
Tue
Wed
Thu
Fri
Sat
Sun
Morningfasted-friendly
GHK-Cu* 6u MOTS-c* yours BPC-157 10u
GHK-Cu* yours SS-31* 25u BPC-157 yours
GHK-Cu* 6u BPC-157 yours
GHK-Cu* 6u MOTS-c* yours BPC-157 10u
GHK-Cu* yours SS-31* 25u BPC-157 yours
—
—
Nighttimeone syringe · FASTED 90m
CJC-1295 10u Ipamorelin yours
CJC-1295 10u Ipamorelin yours
CJC-1295 10u Ipamorelin yours
CJC-1295 10u Ipamorelin yours
CJC-1295 10u Ipamorelin yours
—
Tirzepatide 25u yours · own syringe · not fasted
Weekly: Tirzepatide in your report (2.5 mg) — Sunday evening, own syringe, not fasted. Steps up each month per GI tolerance.
As-needed (no fixed day): PT-141 5–20u — on demand (PT-141 before intimacy). Not part of the weekly rhythm.
Course (this month): Thymosin Alpha-1 10u, Epithalon 50mg 20u — 10 consecutive daily injections, then repeat ~every 3 months (clinician-timed). Not part of the weekly rhythm.
Tirzepatide ~yours 7.5 mg · own syringe · not fasted
Weekly: Tirzepatide ~38u (7.5 mg) — Sunday evening, own syringe, not fasted. Steps up each month per GI tolerance.
As-needed (no fixed day): PT-141 5–20u, Oxytocin 5unew — on demand (PT-141 before intimacy). Not part of the weekly rhythm.
CJC-1295 + Ipamorelin + DSIP draw into one nighttime syringe, taken together at bedtime (fasted 90 min). BPC-157 + AOD-9604 may share one morning syringe, mixed immediately before injection. GHK-Cu, MOTS-c, SS-31, PT-141, Tirzepatide, NAD+, Oxytocin, Thymosin Alpha-1, Epithalon 50mg each get their own syringe. Mix only immediately before injection — never pre-mix in a vial.